| __timestamp | Amgen Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 1860000 |
| Thursday, January 1, 2015 | 4846000000 | 2963000 |
| Friday, January 1, 2016 | 5062000000 | 6961000 |
| Sunday, January 1, 2017 | 4870000000 | 11779000 |
| Monday, January 1, 2018 | 5332000000 | 13697000 |
| Tuesday, January 1, 2019 | 5150000000 | 15749000 |
| Wednesday, January 1, 2020 | 5730000000 | 18638000 |
| Friday, January 1, 2021 | 5368000000 | 27196000 |
| Saturday, January 1, 2022 | 5414000000 | 31739000 |
| Sunday, January 1, 2023 | 6179000000 | 33491000 |
| Monday, January 1, 2024 | 7096000000 |
Unlocking the unknown
In the world of biotechnology, Amgen Inc. and Protagonist Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Amgen's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of Protagonist, reflecting its established market presence. In 2023, Amgen's SG&A expenses reached a staggering $6.2 billion, marking a 31% increase since 2014. Meanwhile, Protagonist's expenses, though modest in comparison, have shown a remarkable growth trajectory, surging by over 1,700% from 2014 to 2023. This dramatic rise underscores Protagonist's aggressive expansion strategy as it seeks to carve out its niche in the competitive biotech landscape. The data reveals not just financial figures but a narrative of growth, ambition, and the contrasting paths of a biotech giant and an emerging player.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Amgen Inc.
Who Optimizes SG&A Costs Better? Amgen Inc. or Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Comparing SG&A Expenses: Amgen Inc. vs TG Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing argenx SE and Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.